Edwards Lifesciences Corp (EW)vsIntegra LifeSciences Holdings (IART)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
IART
Integra LifeSciences Holdings
$9.55
+0.10%
HEALTHCARE · Cap: $696.76M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 271% more annual revenue ($6.07B vs $1.64B). EW leads profitability with a 17.7% profit margin vs -31.6%. IART appears more attractively valued with a PEG of 0.67. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
IART
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Intrinsic value data unavailable for IART.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
0.4% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -39.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : IART
The strongest argument for IART centers on Price/Book, PEG Ratio. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : IART
The primary concerns for IART are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
EW profiles as a mature stock while IART is a turnaround play — different risk/reward profiles.
IART carries more volatility with a beta of 1.02 — expect wider price swings.
EW is growing revenue faster at 13.3% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 52/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Integra LifeSciences Holdings
HEALTHCARE · MEDICAL DEVICES · USA
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?